Cimzia is manufactured by UCB [1].
When does Cimzia's patent protection end?
The patent exclusivity for Cimzia is set to expire in the United States in December 2027 [2]. DrugPatentWatch.com indicates that several patents related to Cimzia will expire between 2024 and 2033 [3].
What is Cimzia used for?
Cimzia is a medication approved to treat moderate to severe active rheumatoid arthritis in adults who have had an inadequate response or intolerance to other therapies [4]. It is also used for active psoriatic arthritis and ankylosing spondylitis [4].
How does Cimzia work?
Cimzia is a tumor necrosis factor (TNF) blocker, a type of biologic medication that works by targeting and neutralizing TNF, a protein that plays a role in inflammation [5]. By reducing TNF, Cimzia helps to decrease inflammation in the body, which can alleviate symptoms of autoimmune diseases [5].
Are there alternatives to Cimzia?
Other TNF blockers available for treating similar conditions include adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade), and certolizumab pegol (which is also a pegylated Fab' fragment of a humanized anti-TNFα monoclonal antibody, similar to Cimzia in its class but with a different specific mechanism and brand name) [6]. These medications offer alternative treatment options for patients with inflammatory conditions.
What are the risks associated with Cimzia?
Cimzia carries risks, including a potential for serious infections, which can be life-threatening [7]. Patients taking Cimzia may also be at increased risk for certain cancers, particularly lymphoma and skin cancer [7]. Other potential risks include allergic reactions, nervous system problems, heart failure, and blood disorders [7].
What is the clinical data supporting Cimzia's use?
Clinical trials have demonstrated Cimzia's efficacy in reducing disease activity and improving physical function in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [8][9]. These studies have shown significant reductions in joint inflammation and pain, as well as improvements in quality of life for treated individuals [8][9].
---
Sources:
1. https://www.ucb.com/
2. https://drugpatentwatch.com/
3. https://drugpatentwatch.com/search/cimzia
4. https://www.cimzia.com/
5. https://www.mayoclinic.org/drugs-supplements/certolizumab-pegol-subcutaneous-route/description/drg-20065754
6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080543/
7. https://www.cimzia.com/important-safety-information
8. https://pubmed.ncbi.nlm.nih.gov/20727443/
9. https://pubmed.ncbi.nlm.nih.gov/22584676/